• About us
• Contact

Advertisement

Organisation › Details

Numab Therapeutics AG

Numab Therapeutics AG is a biopharmaceutical company discovering and developing next-generation therapies for cancer and auto-immune disease. We apply our proprietary antibody discovery engine, Fvstabilizing ?cap™ technology and MATCH™ platform to generate highly versatile multi-specific antibodies with best-in-class properties. Multi-specific MATCH molecules comprise antibody Fvs with fully human frameworks, are highly stable and readily accommodate plug-and-play engineering of novel mechanisms of action (e.g., tumor-targeting T cell-engagers), with superior efficacy and favorable safety profiles. *

 

	Start	2017-03-28 existent
	Group	Numab (Group)
	Industry	antibody technology
	Industry 2	therapeutic antibody
	Person	Urech, David (Numab 201910 CEO + Co-Founder before Esbatech 2004–2010)
	Person 2	Middendorp, Oliver (Numab 201703 CBO + Co-Founder before Esbatech 2004–2010)
	Region	Wädenswil ZH
	Country	Switzerland
	Street	34 Einsiedlerstr.
	City	8820 Wädenswil ZH
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Numab Therapeutics AG. (10/1/19). "Press Release: Numab and Eisai Enter into a Global Research and Option Agreement to Discover and Develop Multi-specific Antibody Immunotherapies for Cancer". Tokyo & Zurich.
		Record changed: 2023-07-31

Advertisement

More documents for Numab (Group)

• [1] Numab Therapeutics AG. (5/20/21). "Press Release: Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing". Wädenswil (Zurich)....
• [2] Numab Therapeutics AG. (1/13/21). "Press Release: Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option". Wädenswil (Zurich)....
• [3] Numab Therapeutics AG. (9/30/20). "Press Release: Numab Therapeutics Appoints Daniel Vasella as New Chairman of the Board". Wädenswil (Zurich)....
• [4] Numab Therapeutics AG. (7/7/20). "Press Release: Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases". Wädenswil & Ingelheim....
• [5] Numab Therapeutics AG. (3/30/20). "Press Release: Numab Therapeutics Expands Immuno-Oncology Research Alliance with Ono Pharmaceutical Co., Ltd.". Wädenswil (Zurich)....
• [6] Numab Therapeutics AG. (3/9/20). "Press Release: Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil (Zurich)....
• [7] Numab Therapeutics AG. (12/12/19). "Press Release: Numab Therapeutics and 3SBio’s Subsidiary Sunshine Guojian Form Partnership to Develop a Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil, Shengyang & Shanghai....
• [8] Numab Therapeutics AG. (10/15/19). "Press Release: Numab Appoints Daniel Vasella to Board of Directors". Wädenswil (Zurich)....
• [9] Numab Therapeutics AG. (10/1/19). "Press Release: Numab and Eisai Enter into a Global Research and Option Agreement to Discover and Develop Multi-specific Antibody Immunotherapies for Cancer". Tokyo & Zurich....
• [10] Numab Therapeutics AG. (5/2/19). "Press Release: CStone and Numab Announce Exclusive Regional Licensing Agreement for ND021, a Multi-functional Drug Candidate and Potential Next-generation Immunotherapy". Suzhou & Pfäffikon....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.